DIKUL - logo

Rezultati iskanja

Osnovno iskanje    Ukazno iskanje   

Trenutno NISTE avtorizirani za dostop do e-virov UL. Za polni dostop se PRIJAVITE.

1 2 3 4 5
zadetkov: 316
1.
  • Plasma P-tau181 in Alzheime... Plasma P-tau181 in Alzheimer's disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer's dementia
    Janelidze, Shorena; Mattsson, Niklas; Palmqvist, Sebastian ... Nature medicine, 03/2020, Letnik: 26, Številka: 3
    Journal Article
    Recenzirano
    Odprti dostop

    Plasma phosphorylated tau181 (P-tau181) might be increased in Alzheimer's disease (AD), but its usefulness for differential diagnosis and prognosis is unclear. We studied plasma P-tau181 in three ...
Celotno besedilo
Dostopno za: UL

PDF
2.
  • Plasma biomarkers of Alzhei... Plasma biomarkers of Alzheimer's disease improve prediction of cognitive decline in cognitively unimpaired elderly populations
    Cullen, Nicholas C; Leuzy, Antoine; Janelidze, Shorena ... Nature communications, 06/2021, Letnik: 12, Številka: 1
    Journal Article
    Recenzirano
    Odprti dostop

    Plasma biomarkers of amyloid, tau, and neurodegeneration (ATN) need to be characterized in cognitively unimpaired (CU) elderly individuals. We therefore tested if plasma measurements of amyloid-β ...
Celotno besedilo
Dostopno za: UL

PDF
3.
  • Cerebrospinal fluid p-tau21... Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer's disease
    Janelidze, Shorena; Stomrud, Erik; Smith, Ruben ... Nature communications, 04/2020, Letnik: 11, Številka: 1
    Journal Article
    Recenzirano
    Odprti dostop

    Cerebrospinal fluid (CSF) p-tau181 (tau phosphorylated at threonine 181) is an established biomarker of Alzheimer's disease (AD), reflecting abnormal tau metabolism in the brain. Here we investigate ...
Celotno besedilo
Dostopno za: UL

PDF
4.
  • Prediction of future Alzheimer's disease dementia using plasma phospho-tau combined with other accessible measures
    Palmqvist, Sebastian; Tideman, Pontus; Cullen, Nicholas ... Nature medicine, 06/2021, Letnik: 27, Številka: 6
    Journal Article
    Recenzirano
    Odprti dostop

    A combination of plasma phospho-tau (P-tau) and other accessible biomarkers might provide accurate prediction about the risk of developing Alzheimer's disease (AD) dementia. We examined this in ...
Celotno besedilo
Dostopno za: UL

PDF
5.
  • Blood‐based biomarkers for ... Blood‐based biomarkers for Alzheimer's disease
    Leuzy, Antoine; Mattsson‐Carlgren, Niklas; Palmqvist, Sebastian ... EMBO molecular medicine, 11 January 2022, Letnik: 14, Številka: 1
    Journal Article
    Recenzirano
    Odprti dostop

    Neurodegenerative disorders such as Alzheimer's disease (AD) represent a mounting public health challenge. As these diseases are difficult to diagnose clinically, biomarkers of underlying ...
Celotno besedilo
Dostopno za: UL

PDF
6.
  • Longitudinal plasma p-tau21... Longitudinal plasma p-tau217 is increased in early stages of Alzheimer's disease
    Mattsson-Carlgren, Niklas; Janelidze, Shorena; Palmqvist, Sebastian ... Brain (London, England : 1878), 12/2020, Letnik: 143, Številka: 11
    Journal Article
    Recenzirano
    Odprti dostop

    Plasma levels of tau phosphorylated at threonine-217 (p-tau217) is a candidate tool to monitor Alzheimer's disease. We studied 150 cognitively unimpaired participants and 100 patients with mild ...
Celotno besedilo
Dostopno za: UL

PDF
7.
  • Discriminative Accuracy of ... Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders
    Palmqvist, Sebastian; Janelidze, Shorena; Quiroz, Yakeel T ... JAMA : the journal of the American Medical Association, 08/2020, Letnik: 324, Številka: 8
    Journal Article
    Recenzirano
    Odprti dostop

    IMPORTANCE: There are limitations in current diagnostic testing approaches for Alzheimer disease (AD). OBJECTIVE: To examine plasma tau phosphorylated at threonine 217 (P-tau217) as a diagnostic ...
Celotno besedilo
Dostopno za: CMK

PDF
8.
  • Concordance Between Differe... Concordance Between Different Amyloid Immunoassays and Visual Amyloid Positron Emission Tomographic Assessment
    Janelidze, Shorena; Pannee, Josef; Mikulskis, Alvydas ... JAMA neurology, 12/2017, Letnik: 74, Številka: 12
    Journal Article
    Recenzirano
    Odprti dostop

    IMPORTANCE: Visual assessment of amyloid positron emission tomographic (PET) images has been approved by regulatory authorities for clinical use. Several immunoassays have been developed to measure ...
Celotno besedilo
Dostopno za: CMK

PDF
9.
  • Cerebrospinal fluid and pla... Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer's disease
    Palmqvist, Sebastian; Insel, Philip S; Stomrud, Erik ... EMBO molecular medicine, December 2019, Letnik: 11, Številka: 12
    Journal Article
    Recenzirano
    Odprti dostop

    Failures in Alzheimer's disease (AD) drug trials highlight the need to further explore disease mechanisms and alterations of biomarkers during the development of AD. Using cross‐sectional data from ...
Celotno besedilo
Dostopno za: UL

PDF
10.
  • The implications of differe... The implications of different approaches to define AT(N) in Alzheimer disease
    Mattsson-Carlgren, Niklas; Leuzy, Antoine; Janelidze, Shorena ... Neurology, 2020-May-26, 2020-05-26, 20200526, Letnik: 94, Številka: 21
    Journal Article
    Recenzirano
    Odprti dostop

    OBJECTIVETo compare different β-amyloid (Aβ), tau, and neurodegeneration (ATN) variants within the Swedish BioFINDER studies. METHODSA total of 490 participants were classified into AT(N) groups. ...
Celotno besedilo
Dostopno za: UL

PDF
1 2 3 4 5
zadetkov: 316

Nalaganje filtrov